-

Natera to Participate in Goldman Sachs 44th Annual Global Healthcare Conference

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its management team will present at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13 at 5:40 pm ET | 2:40 pm PT in Dana Point, CA.

A live webcast and audio archive of the event may be accessed through the investor relations section of the Natera website at investor.natera.com. A replay of the event will be available shortly following the conference.

About Natera

Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.

Contacts

Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com

Industry:

Natera, Inc.

NASDAQ:NTRA
Release Versions
English

Contacts

Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com

More News From Natera, Inc.

Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved Signatera CDx as a companion diagnostic (CDx) for use with adjuvant atezolizumab (Tecentriq®) immunotherapy in MIBC. This is the first companion diagnostic approval in the field of blood-based MRD. It is a significant milestone in the industry-wide shift toward personalized, MRD-guided cancer care, in...

Natera Reports First Quarter 2026 Financial Results

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2026. Recent Financial Highlights Generated total revenues of $696.6 million in the first quarter of 2026, compared to $501.8 million in the first quarter of 2025, an increase of 38.8%. Generated a gross margin1 of 64.7% in the first quarter of 2026, compared to a gross margin1 of 63.1% in the first quarter...

Natera to Report its First Quarter Results on May 7, 2026

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its first quarter ended March 31, 2026, after the market closes on May 7, 2026. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information Event: Natera’s First Quarter 2026 Financial Results Date: May 7, 2026 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In...
Back to Newsroom